{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:18:52Z","timestamp":1776277132221,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Gueules Cass\u00e9es Foundation"},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004099","name":"Ligue National Contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005853","name":"University of Chile","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005853","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CONICYT- Becas Chile","award":["79090016"],"award-info":[{"award-number":["79090016"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cranio-Maxillofacial Surgery"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jcms.2016.07.015","type":"journal-article","created":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T01:11:27Z","timestamp":1469236287000},"page":"1387-1394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw"],"prefix":"10.1016","volume":"44","author":[{"given":"Luis A.","family":"C\u00f3rdova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Guilbaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Amiaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Charrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lezot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Piot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Redini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jcms.2016.07.015_bib1","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jbmr.379","article-title":"Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat","volume":"26","author":"Aghaloo","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1016\/j.jcms.2016.07.015_bib2","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J\u00a0Bone Miner Res: Off J Am Soc Bone Miner Res"},{"issue":"11","key":"10.1016\/j.jcms.2016.07.015_bib3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1517\/17425255.4.11.1371","article-title":"Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment","volume":"4","author":"Allen","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.jcms.2016.07.015_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.joms.2008.01.038","article-title":"Mandible matrix necrosis in Beagle dogs after 3 years of daily oral bisphosphonate treatment","volume":"66","author":"Allen","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg: Off J Am Assoc Oral Maxillofac Surg"},{"issue":"5 Suppl","key":"10.1016\/j.jcms.2016.07.015_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg: Off J Am Assoc Oral Maxillofac Surg"},{"issue":"6","key":"10.1016\/j.jcms.2016.07.015_bib6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000351194","article-title":"Zoledronic acid inhibits human osteoblast activities","volume":"59","author":"Basso","year":"2013","journal-title":"Gerontology"},{"issue":"1","key":"10.1016\/j.jcms.2016.07.015_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","article-title":"Bisphosphonates cause osteonecrosis of the jaw-like disease in mice","volume":"177","author":"Bi","year":"2010","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.jcms.2016.07.015_bib8","doi-asserted-by":"crossref","first-page":"e48648","DOI":"10.1371\/journal.pone.0048648","article-title":"Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells","volume":"7","author":"Bouacida","year":"2012","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.jcms.2016.07.015_bib9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental Breast Cancer bone metastasis","volume":"99","author":"Daubin\u00e9","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.jcms.2016.07.015_bib10","first-page":"222","article-title":"Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw associated with dental implants","volume":"24","author":"Doh","year":"2015","journal-title":"Implant Dent"},{"issue":"24","key":"10.1016\/j.jcms.2016.07.015_bib11","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J\u00a0Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.jcms.2016.07.015_bib12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm.3653","article-title":"Preparing the Ground for tissue regeneration: from mechanism to therapy","volume":"20","author":"Forbes","year":"2014","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.jcms.2016.07.015_bib13","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in\u00a0vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jcms.2016.07.015_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.canlet.2013.11.017","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in\u00a0vivo with an improved survival rate","volume":"344","author":"Gobin","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jcms.2016.07.015_bib15","article-title":"BYL719, a new \u03b1-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma","author":"Gobin","year":"2014","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.jcms.2016.07.015_bib16","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/stem.1040","article-title":"Induction of osteogenesis in mesenchymal stem cells by activated monocytes\/macrophages depends on oncostatin M signaling","volume":"30","author":"Guihard","year":"2012","journal-title":"Stem Cells"},{"issue":"3","key":"10.1016\/j.jcms.2016.07.015_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates \u2013 Histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"J\u00a0Oral Pathol Med: Off Pub Int Assoc Oral Pathol Am Acad Oral Pathol"},{"issue":"1","key":"10.1016\/j.jcms.2016.07.015_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"Bone"},{"issue":"27","key":"10.1016\/j.jcms.2016.07.015_bib19","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.2174\/138161210793563572","article-title":"Bisphosphonates and bone diseases: past, present and future","volume":"16","author":"Heymann","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"7","key":"10.1016\/j.jcms.2016.07.015_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.molmed.2004.05.007","article-title":"Bisphosphonates: new therapeutic agents for the treatment of bone tumors","volume":"10","author":"Heymann","year":"2004","journal-title":"Trends Mol Med"},{"issue":"6","key":"10.1016\/j.jcms.2016.07.015_bib21","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J\u00a0Bone Miner Res: Off J Am Soc Bone Miner Res"},{"issue":"16","key":"10.1016\/j.jcms.2016.07.015_bib22","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMc090167","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Jobke","year":"2009","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.jcms.2016.07.015_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/03008200802412462","article-title":"Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest","volume":"50","author":"Jobke","year":"2009","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.jcms.2016.07.015_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2593","article-title":"Response to comments on \u201cdiagnosis and management of osteoporosis of the jaw: a systematic review and international consensus\u201d","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.jcms.2016.07.015_bib25","first-page":"348","article-title":"Osteonecrosis and osteonecrosis of the jaw (ONJ)","volume":"7","author":"Kim","year":"2007","journal-title":"J\u00a0Musculoskelet Neuronal Interact"},{"issue":"6","key":"10.1016\/j.jcms.2016.07.015_bib26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0022034511402995","article-title":"Bisphosphonates induce senescence in normal human oral keratinocytes","volume":"90","author":"Kim","year":"2011","journal-title":"J\u00a0Dent Res"},{"issue":"8","key":"10.1016\/j.jcms.2016.07.015_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jcms.2010.10.007","article-title":"Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner\u2014a quantitative in\u00a0vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2","volume":"39","author":"Koch","year":"2011","journal-title":"J\u00a0Cranio-Maxillo-Facial Surg: Off Pub Eur Assoc Cranio-Maxillo-Facial Surg"},{"key":"10.1016\/j.jcms.2016.07.015_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4511","article-title":"Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle","volume":"5","author":"Lamoureux","year":"2014","journal-title":"Nature Commun"},{"issue":"27","key":"10.1016\/j.jcms.2016.07.015_bib29","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.2174\/138161210793563563","article-title":"A\u00a0comparison between bisphosphonates and other treatments for osteoporosis","volume":"16","author":"Le Goff","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jcms.2016.07.015_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2013.10.002","article-title":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in Cancer patients","volume":"58","author":"Lescaille","year":"2014","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.jcms.2016.07.015_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?","volume":"45","author":"Lesclous","year":"2009","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.jcms.2016.07.015_bib32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jcms.2014.12.008","article-title":"High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis","volume":"43","author":"Manzano-Moreno","year":"2015","journal-title":"J\u00a0Cranio-Maxillo-Facial Surg: Off Pub Eur Assoc Cranio-Maxillo-Facial Surg"},{"key":"10.1016\/j.jcms.2016.07.015_bib33","article-title":"Development of a rat model of bisphosphonate-related osteonecrosis of the jaw (BRONJ)","author":"Marino","year":"2011","journal-title":"J\u00a0Oral Implantol"},{"issue":"9","key":"10.1016\/j.jcms.2016.07.015_bib34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg: Off J Am Assoc Oral Maxillofac Surg"},{"issue":"11","key":"10.1016\/j.jcms.2016.07.015_bib35","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"11","key":"10.1016\/j.jcms.2016.07.015_bib36","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1177\/0022034511420430","article-title":"A\u00a0role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw","volume":"90","author":"Mawardi","year":"2011","journal-title":"J\u00a0Dent Res"},{"issue":"7","key":"10.1016\/j.jcms.2016.07.015_bib37","doi-asserted-by":"crossref","first-page":"e39871","DOI":"10.1371\/journal.pone.0039871","article-title":"Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation","volume":"7","author":"Nicolaidou","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jcms.2016.07.015_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/ken462","article-title":"Femoral head osteonecrosis can be caused by disruption of the systemic immune response via the toll-like receptor 4 signalling pathway","volume":"48","author":"Okazaki","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jcms.2016.07.015_bib39","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00784-013-1060-x","article-title":"Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in\u00a0vivo 3D matrigel assay","volume":"18","author":"Pabst","year":"2014","journal-title":"Clin Oral Invest"},{"issue":"3","key":"10.1016\/j.jcms.2016.07.015_bib40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/jnci\/djq516","article-title":"Osteonecrosis of the jaw and the role of macrophages","volume":"103","author":"Pazianas","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.jcms.2016.07.015_bib41","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-09-0426","article-title":"High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties","volume":"15","author":"Pozzi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jcms.2016.07.015_bib42","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","article-title":"Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw","volume":"14","author":"Raje","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.jcms.2016.07.015_bib43","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5 Suppl","key":"10.1016\/j.jcms.2016.07.015_bib44","first-page":"2","article-title":"American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg: Off J Am Assoc Oral Maxillofac Surg"},{"issue":"7\u20138","key":"10.1016\/j.jcms.2016.07.015_bib45","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.micron.2005.06.008","article-title":"Reduced osteoblastic population and defective mineralization in osteopetrotic (op\/op) mice","volume":"36","author":"Sakagami","year":"2005","journal-title":"Micron (Oxford, Engl: 1993)"},{"issue":"8","key":"10.1016\/j.jcms.2016.07.015_bib46","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jcms.2016.07.015_bib47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-014-0196-1","article-title":"Implications of osteoblast\u2013osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib","volume":"12","author":"Sims","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.jcms.2016.07.015_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/bonekey.2013.215","article-title":"Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit","volume":"3","author":"Sims","year":"2014","journal-title":"BoneKEy Reports"},{"issue":"2","key":"10.1016\/j.jcms.2016.07.015_bib49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2010.09.035","article-title":"Nitrogen-containing bisphosphonates can inhibit angiogenesis in\u00a0vivo without the involvement of farnesyl pyrophosphate synthase","volume":"48","author":"Stresing","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.jcms.2016.07.015_bib50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1601-0825.2010.01720.x","article-title":"Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in\u00a0vitro","volume":"17","author":"Walter","year":"2011","journal-title":"Oral Dis"},{"issue":"1","key":"10.1016\/j.jcms.2016.07.015_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.jcms.2016.07.015_bib52","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2016.07.015_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpath.2014.07.010","article-title":"Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti\u2013 receptor activator of NF-\u03baB ligand antibody in mice","author":"Williams","year":"2014","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.jcms.2016.07.015_bib54","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J\u00a0Pharmacol Experiment Ther"},{"issue":"1","key":"10.1016\/j.jcms.2016.07.015_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00784-009-0365-2","article-title":"Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in\u00a0vitro","volume":"15","author":"Ziebart","year":"2011","journal-title":"Clin Oral Invest"}],"container-title":["Journal of Cranio-Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518216301494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518216301494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:38:15Z","timestamp":1760884695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1010518216301494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1010518216301494"],"URL":"https:\/\/doi.org\/10.1016\/j.jcms.2016.07.015","relation":{},"ISSN":["1010-5182"],"issn-type":[{"value":"1010-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw","name":"articletitle","label":"Article Title"},{"value":"Journal of Cranio-Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcms.2016.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}